Head to Head Contrast: Ayala Pharmaceuticals (NASDAQ:ADXS) & Petros Pharmaceuticals (NASDAQ:PTPI)

Risk & Volatility

Ayala Pharmaceuticals has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500.

Insider & Institutional Ownership

7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Comparatively, 12.2% of Petros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Ayala Pharmaceuticals and Petros Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

Earnings & Valuation

This table compares Ayala Pharmaceuticals and Petros Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24 million	11.05	-$48.07 million	($5.02)	-0.12
Petros Pharmaceuticals	$5.11 million	0.02	-$8.16 million	($1.64)	-0.00

Petros Pharmaceuticals has higher revenue and earnings than Ayala Pharmaceuticals. Ayala Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Petros Pharmaceuticals beats Ayala Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.